New Tests
Catch Up with New and Enhanced Tests in All Methodologies
Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. We are continually refining and adding new assays in hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.
Please Review Our List of Recently Launched Tests:
- 1p36 Deletion (12-20-19)
- CD68 (PG-M1) (12-20-19)
- CD103 (12-20-19)
- NeoTYPE®HRD+ Profile (11-4-19)
- NTRK 1, 2, 3 FISH Panel (11-4-19)
- COMPASS® (10-21-19)
- NTRK3 FISH (10-21-19)
- TCR Delta IHC (10-14-19)
- Breast Cancer Index® (10-1-19)
- Prosigna® Assay (10-1-19)
- PD-L1 22C3 FDA (KEYTRUDA®) for ESCC (Esophageal Squamous Cell Carcinoma) (8-20-19)
- BRCA1/2 Mutation Analysis for Tumors (6-30-19)
- PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck) (6-10-19)
- PIK3CA Mutation CDx – Tissue (5-28-19)
- FGFR CDx Molecular Analysis (5-15-19)
- PD-L1 SP142 FDA (TECENTRIQ®) for TNBC (3-11-19)